GSK3B and neoplasm: We found phosphorylation of Fas (Figure 7A) or Gsk3β (Figure 7B) in viable CD133+ tumor cells from mice treated with SLV peptide, which increased in mice undergoing combined treatment with oxaliplatin and SLV.